COMMUNIQUÉS West-GlobeNewswire

Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
24/04/2025
>8,500 samples and 100 million cells of high resolution and fully annotated spatial proteomics data available MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial [...]
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
24/04/2025
April 28 th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be held on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 24, 2025 [...]
Autonomize AI Prior Authorization Copilot: Helping Patients Get Care Faster, Safer, and with Less Stress
24/04/2025
AUSTIN, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomize AI, the leader in healthcare-native AI, today announced a major update to its Prior Authorization Copilot that is delivering rapid, patient-centered [...]
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
24/04/2025
ADC assay now available through ABS; customer study proves IO60 is a spatial workhorse MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, today [...]
ORYZON Raises €30 Million in Capital Increase
24/04/2025
Issued 12,765,958 new shares Priced at €2.35 per share, representing a 15.44% discount on the 5-day VWAP Strong investor demand, with the offering significantly oversubscribed €15 million anchored by a leading US [...]
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
24/04/2025
WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with [...]
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025
24/04/2025
TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 [...]
Nerve Renew Under Review & Ingredients Guide | Best Nerve Pain Supplement Explained
24/04/2025
Nerve Renew is a dietary supplement formulated to support nerve health, particularly for individuals experiencing symptoms of peripheral neuropathy such as tingling, numbness, burning sensations, or nerve pain Eagle, [...]
RadNet, Inc. Announces Date of its First Quarter 2025 Financial Results Conference Call
24/04/2025
LOS ANGELES, April 24, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
24/04/2025
Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical-stage [...]
Composition of the Nomination Committee of Orion Corporation
24/04/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 24 APRIL 2025 at 11.00 EEST Composition of the Nomination Committee of Orion Corporation The Board of [...]
New survey shows that over 90% of animal owners trust and appreciate veterinary teams but underestimate the demands of the profession
24/04/2025
New survey data show 94% of animal owners appreciate the work of veterinarians 1 , compared to only 49% of veterinary professionals feeling their profession is appreciated, among other findings. 2 The survey confirms [...]
iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial
24/04/2025
For immediate release iSTAR Medical’s MINIject ® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial Five-year safety profile including corneal health confirmed and 38% IOP [...]
Actimed Therapeutics Appoints Shaun Claydon as Chief Financial Officer
24/04/2025
London, UK – 24 th April 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
24/04/2025
Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive exploratory and efficacy outcomes Preparations underway to initiate [...]
Bioxodes annonce des données intermédiaires positives pour son essai de phase 2a portant sur BIOX-101 dans le traitement de l’AVC hémorragique
24/04/2025
Le critère d’évaluation principal a été atteint, aucun événement indésirable grave associé au médicament n’a été rapporté L’évolution du volume de l’hématome et de l’œdème est favorable Le recrutement des patients a été [...]
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
24/04/2025
Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options Patients treated [...]
Les dernières données sur l’élafibranor démontrent un profil de tolérance favorable et une efficacité significative dans la CSP, une deuxième indication dans les maladies rares du foie
24/04/2025
L’élafibranor a montré un profil de tolérance favorable et a démontré une efficacité en termes de relation dose-effet sur 12 semaines chez des patients atteints de CSP, une maladie rare du foie pour laquelle il n’existe [...]
Pharming Group to report first quarter 2025 financial results on May 8
24/04/2025
Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period [...]

Pages